<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587741</url>
  </required_header>
  <id_info>
    <org_study_id>Third SunYetSan</org_study_id>
    <nct_id>NCT02587741</nct_id>
  </id_info>
  <brief_title>Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens</brief_title>
  <acronym>CORRECT</acronym>
  <official_title>Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens: a Multicentre Randomized Parallel-group Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is an important cause of blindness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic retinopathy (DR) is an important cause of blindness, and its development of an
      irreversible process. DR is not only the overall progress and the level of blood sugar, and
      blood glucose fluctuations more closely, is the key to a smooth hypoglycemic delay DR
      progression.Diabetes control and complication trail(DCCT) study shows that even though
      glycemic control was no significant difference in blood glucose fluctuations ,DR also have a
      significant difference. In this study, three different glucose-lowering program for: (A) a
      single oral anti-diabetic drugs, (B) basal insulin and oral anti-diabetic drugs, (C) premixed
      insulin and oral anti-diabetic drugs for comparison. Focus on the stability and the impact of
      these three programs hypoglycemic long-term prognosis of the DR, and thus affect the
      molecular mechanisms of DR-based exploration of glucose fluctuations, to optimize blood
      glucose solutions, lower blood sugar steady, slow progression of DR ultimate clinical
      purposes.

      The multi-center study is to cooperate, enrolled 600 cases of type 2 diabetes, observe the
      effects of different solutions on blood sugar glucose fluctuations and retinopathy, a total
      of 5 years of follow-up. This will be the first at home and abroad to compare the incidence
      of hypoglycemic effect programs on DR large multi-center, randomized, controlled clinical
      studies, clinical practice will optimize the treatment of type 2 diabetes theoretical and
      evidence-based medicine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of diabetic retinopathy</measure>
    <time_frame>5years</time_frame>
    <description>5-year incidence rate of diabetic retinopathy（%）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>5 years</time_frame>
    <description>myocardial infarction, angina,or cardiac insufficiency with other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal failure</measure>
    <time_frame>5years</time_frame>
    <description>use urinary protein excretion rate（%） evaluate clinical course of diabetic nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose fluctuation</measure>
    <time_frame>every one year in 5years</time_frame>
    <description>we use continuous glucose monitoring system（CGMS）,made by Medtronic company USA,and assess within-day blood glucose excursions,Daytime blood sugar stability and the stability of postprandial blood glucose,including Standard Deviation Of Blood Glucose（SDBG）in mmol/L, largest amplitude of glycemic excursions(LAGE)in mmol/L, mean amplitude of glycemic excursions(MAGE) in mmol/L,low glycemic index(LBMI),coefficient variation fasting glucose parameters,Mean Of Daily Differences(MODD)in mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxidative stress</measure>
    <time_frame>every one year in 5 years</time_frame>
    <description>Glyoxalase 1(GLO-1)in pg/ml,Advanced glycation end products(AGEs）in pg/ml,Soluble Receptor for advanced glycation end products(sRAGE）in pg/ml.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Metabolic indices</measure>
    <time_frame>every three months in 5 years</time_frame>
    <description>Fasting blood glucose（FBG）in mmol/L, postprandial blood glucose（PBG）in mmol/L, glycosylated hemoglobin（GHbA1c）in percentage.total cholesterol（TC), low density lipoprotein(LDL) and high density lipoprotein(HDL)in mmol/L.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>oral drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral anti-diabetic drugs only.metformin,start from 500mg bid,if blood glucose dose not reach the standard，added to 500mg tid→1000mg bid.if metformin reach the biggest dosage，added gliclazide modified release tablets，from 30mg qd,if blood glucose dose not reach the standard,add dosage 30mg qd→60 mg qd→90mg qd→120mg qd(max).if still not reach the target，add acarbose 50mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lantus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>basal insulin combine with oral drugs,started with insulin glargine 0.2 u/kg subcutaneous injection at 10pm（at 8am if patients are night workers）,add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novomix30</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>premixed insulin combine with oral drugs,started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose</description>
    <arm_group_label>oral drugs</arm_group_label>
    <other_name>gliclazide modified release tablets</other_name>
    <other_name>acarbose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus</intervention_name>
    <description>started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）</description>
    <arm_group_label>lantus</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>gliclazide modified release tablets</other_name>
    <other_name>acarbose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novomix30</intervention_name>
    <description>started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs</description>
    <arm_group_label>Novomix30</arm_group_label>
    <other_name>Metformin</other_name>
    <other_name>gliclazide modified release tablets</other_name>
    <other_name>acarbose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. aged 30-65;

          2. diagnosed to be type 2 diabetes in accordance with the WHO diagnostic criteria in 1999
             .

          3. diabetes duration for 5 years or less;

          4. the glycosylated hemoglobin (HbA1c) is higher than or equal to7.0% ;

          5. body mass index (BMI) 20-35 kg/m2;

          6. fluorescein fundus angiography (FFA) showed no diabetic retinopathy;

          7. women of childbearing-age have birth control plan for 5 years plan;

        Exclusion Criteria:

          1. pregnant or lactating women;

          2. diabetes autoantibodies (GAD) antibodies positive;

          3. occurred state of diabetic ketoacidosis, diabetes, high permeability, diabetes lactic
             acidosis within a half years ;

          4. aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 times higher than
             normal ceiling, and/or serum creatinine (Cr) or 133 umol/l (1.5 mg/dl);

          5. hemoglobin disease history which can affect determination of HbA1c;

          6. have received a coronary angioplasty, coronary artery stent implantation, coronary
             artery bypass surgery, there was myocardial infarction, unstable angina, and clinical
             significance of abnormal ecg, cerebrovascular accident, or transient ischemic attack.

          7. psychiatric patients;

          8. any eye eyesight &lt; 0.1 patients (WHO blind eye disease: keratitis, need serious
             cataract surgery, glaucoma, uveitis, high myopia shaft &gt; 26.5 mm, history of ocular
             trauma;Other ophthalmology medical history: the central vein occlusion, branch vein
             occlusion, wet sex senile macular degeneration, etc.;

          9. in eye surgery history, history of cataract surgery, and three months; Other serious
             diseases, the researchers think that don't fit into the patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mu panwei, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Employ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen Yanming, Doctor</last_name>
    <phone>+8618922102818</phone>
    <email>1211587508@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhu Bilian, Master</last_name>
    <phone>+8613580364394</phone>
    <email>bilianzhu@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the third affiliated hospital of Sun yet-san university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Bilian, master</last_name>
      <phone>+8613580364394</phone>
      <email>bilianzhu@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Tang Xixiang, master</last_name>
      <phone>+8613570434387</phone>
      <email>txx_8711@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007 Jul-Aug;14(4):179-83. Review.</citation>
    <PMID>17896294</PMID>
  </results_reference>
  <results_reference>
    <citation>Kempen JH, O'Colmain BJ, Leske MC, Haffner SM, Klein R, Moss SE, Taylor HR, Hamman RF; Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):552-63.</citation>
    <PMID>15078674</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischbacher CM, Bhopal R, Unwin N, Walker M, White M, Alberti KG. Maternal transmission of type 2 diabetes varies by ethnic group: cross-sectional survey of Europeans and South Asians. Diabetes Care. 2001 Sep;24(9):1685-6.</citation>
    <PMID>11522720</PMID>
  </results_reference>
  <results_reference>
    <citation>Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, Verlato G. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000 Jan;23(1):45-50.</citation>
    <PMID>10857967</PMID>
  </results_reference>
  <results_reference>
    <citation>White NH, Sun W, Cleary PA, Danis RP, Davis MD, Hainsworth DP, Hubbard LD, Lachin JM, Nathan DM. Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol. 2008 Dec;126(12):1707-15. doi: 10.1001/archopht.126.12.1707.</citation>
    <PMID>19064853</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complications. 2011 Sep-Oct;25(5):332-8. doi: 10.1016/j.jdiacomp.2011.06.004. Epub 2011 Aug 2.</citation>
    <PMID>21813293</PMID>
  </results_reference>
  <results_reference>
    <citation>Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. Clin Exp Pharmacol Physiol. 2010 May;37(5-6):564-8. doi: 10.1111/j.1440-1681.2010.05361.x. Epub 2010 Jan 17.</citation>
    <PMID>20082624</PMID>
  </results_reference>
  <results_reference>
    <citation>Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Diabet Med. 2006 May;23(5):522-8.</citation>
    <PMID>16681561</PMID>
  </results_reference>
  <results_reference>
    <citation>Mu P, Lu H, Zhang G, Chen Y, Fu J, Wang M, Shu J, Zeng L. Comparison of fasting capillary glucose variability between insulin glargine and NPH. Diabetes Res Clin Pract. 2011 Jan;91(1):e4-7. doi: 10.1016/j.diabres.2010.09.026.</citation>
    <PMID>20970870</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 25, 2015</last_update_submitted>
  <last_update_submitted_qc>October 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yanming Chen</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus</keyword>
  <keyword>Diabetic Retinopathy</keyword>
  <keyword>glucose fluctuation</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>Insulin</keyword>
  <keyword>Oral drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

